Sentiment-Signal
5,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (27.03.2026)
HOCH Abgang Schlüsselpersonen (02.03.2026)
HOCH Abgang Schlüsselpersonen (27.02.2026)
HOCH Abgang Schlüsselpersonen (27.03.2026)
HOCH Abgang Schlüsselpersonen (02.03.2026)
HOCH Abgang Schlüsselpersonen (27.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ☐ Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; CO |
| 02.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 2026 to remove two sentences. Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT |
| 27.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ☐ Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; CO |
| 14.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 06.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 07.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; CO |
| 12.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
Stammdaten
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Unternehmen & Branche
| Name | PULSE BIOSCIENCES, INC. |
|---|---|
| Ticker | PLSE |
| CIK | 0001625101 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Instruments & Supplies |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,48 Mrd. USD |
| Beta | 1,69 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 350,000 | -72,781,000 | 94,539,000 | 80,656,000 | |
| 2025-09-30 | 10-Q | 86,000 | -19,385,000 | 108,765,000 | 92,694,000 | |
| 2025-06-30 | 10-Q | 0 | -19,168,000 | 120,251,000 | 104,487,000 | |
| 2025-03-31 | 10-Q | 0 | -16,795,000 | 133,383,000 | 118,452,000 | |
| 2024-12-31 | 10-K | 0 | -53,585,000 | 132,460,000 | 114,862,000 | |
| 2024-09-30 | 10-Q | 0 | -12,680,000 | 93,046,000 | 79,131,000 | |
| 2024-06-30 | 10-Q | 0 | -11,383,000 | 40,428,000 | 26,969,000 | |
| 2024-03-31 | 10-Q | 0 | -10,137,000 | 49,164,000 | 36,287,000 | |
| 2023-12-31 | 10-K | 0 | -42,210,000 | 59,154,000 | 44,360,000 | |
| 2023-09-30 | 10-Q | 0 | -10,566,000 | 65,945,000 | 52,145,000 | |
| 2023-06-30 | 10-Q | 0 | -9,910,000 | 74,757,000 | 60,500,000 | |
| 2023-03-31 | 10-Q | 0 | -9,801,000 | 70,221,000 | -10,667,000 | |
| 2022-12-31 | 10-K | 700,000 | -58,505,000 | 77,877,000 | -2,248,000 | |
| 2022-09-30 | 10-Q | 0 | -18,039,000 | -0.49 | 87,570,000 | 6,189,000 |
| 2022-06-30 | 10-Q | 265,000 | -13,996,000 | -0.44 | 40,597,000 | 23,415,000 |
| 2022-03-31 | 10-Q | 444,000 | -17,273,000 | 39,534,000 | 20,796,000 | |
| 2021-12-31 | 10-K | 1,418,000 | -63,660,000 | 54,249,000 | 35,690,000 | |
| 2021-09-30 | 10-Q | 574,000 | -14,282,000 | -0.48 | 67,148,000 | 47,387,000 |
| 2021-06-30 | 10-Q | -15,323,000 | -0.58 | 80,039,000 | 59,750,000 | |
| 2021-03-31 | 10-Q | -18,639,000 | 80,557,000 | 20,397,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-17 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -20,000 | 16.21 | -324,200.00 | -91,1% | |
| 2025-09-16 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -25,000 | 16.28 | -407,000.00 | -114,4% | |
| 2025-09-15 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -25,000 | 15.77 | -394,250.00 | -110,8% | |
| 2025-09-12 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -25,000 | 14.32 | -358,000.00 | -100,6% | |
| 2025-09-11 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -25,000 | 14.78 | -369,500.00 | -103,8% | |
| 2025-09-10 | DUGGAN ROBERT W | Director, 10% Owner | Open Market Purchase | 34,659 | 14.66 | 508,100.94 | +142,8% | |
| 2025-06-13 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -15,000 | 15.98 | -239,700.00 | -67,4% | |
| 2025-06-12 | UECKER DARRIN | Director, Officer, Chief Technology Officer | Open Market Sale | -15,000 | 16.40 | -246,000.00 | -69,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.